This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Tobacco  • Chronic Obstructive Pulmonary Disease  • Alert me on articles by topic

E. J. Wagena, PhD; P. G. Knipschild, MD, PhD; M. J. H. Huibers, PhD; E. F. M. Wouters, MD, PhD; C. P. van Schayck, PhD

Arch Intern Med. 2005;165:2286-2292.

Background  The observations that smokers with chronic obstructive pulmonary disease (COPD) are at increased risk of depression and that nicotine may have antidepressant effects and regulate mood provide a rationale for the use of antidepressant drugs for smoking cessation in patients with COPD. No clinical trial has studied the efficacy of bupropion hydrochloride and nortriptyline hydrochloride for smoking cessation in this patient population, to our knowledge.

Methods  In a placebo-controlled double-dummy randomized trial, 255 adults at risk for COPD or with COPD were prescribed sustained-release bupropion (bupropion SR) (150 mg twice daily) or nortriptyline (75 mg once daily) for 12 weeks. All patients received smoking cessation counseling. The main outcome measure was prolonged abstinence from smoking from week 4 to week 26 after the target quit date.

Results  The use of bupropion SR and nortriptyline resulted in higher prolonged abstinence rates compared with placebo, although only the difference between bupropion SR and placebo was statistically significant (differences with placebo, 13.1% [95% confidence interval, 1.2%-25.1%] for bupropion SR and 10.2% [95% confidence interval, –1.7% to 22.2%] for nortriptyline). In patients with COPD, bupropion SR and nortriptyline seem efficacious in achieving prolonged abstinence (differences with placebo, 18.9% [95% confidence interval, 3.6%-34.2%] for bupropion SR and 12.9% [95% confidence interval, –0.8% to 26.4%] for nortriptyline). In participants at risk for COPD, no statistically significant differences with placebo in prolonged abstinence rates were found.

Conclusions  Bupropion SR treatment is an efficacious aid to smoking cessation in patients with COPD. Nortriptyline treatment seems to be a useful alternative.

Author Affiliations: Departments of General Practice (Drs Wagena, Knipschild, and van Schayck), Medical, Experimental, and Clinical Psychology (Dr Huibers), and Respiratory Medicine (Dr Wouters), Maastricht University, Maastricht; and Pulmonary Rehabilitation Centre Hornerheide, Horn (Dr Wagena); the Netherlands. Dr Wagena is now with Solvay Pharmaceuticals, Weesp, the Netherlands.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Depressive Symptoms and Smoking Cessation After Hospitalization for Cardiovascular Disease
Thorndike et al.
Arch Intern Med 2008;168:186-191.
ABSTRACT | FULL TEXT  

Depressive Symptoms and Chronic Obstructive Pulmonary Disease: Effect on Mortality, Hospital Readmission, Symptom Burden, Functional Status, and Quality of Life
Ng et al.
Arch Intern Med 2007;167:60-67.
ABSTRACT | FULL TEXT  

Efficacy and Safety of the Novel Selective Nicotinic Acetylcholine Receptor Partial Agonist, Varenicline, for Smoking Cessation.
Oncken et al.
Arch Intern Med 2006;166:1571-1577.
ABSTRACT | FULL TEXT  

Nurse-Conducted Smoking Cessation in Patients With COPD Using Nicotine Sublingual Tablets and Behavioral Support.
Tonnesen et al.
Chest 2006;130:334-342.
ABSTRACT | FULL TEXT  

Update in chronic obstructive pulmonary disease 2005.
Fabbri et al.
Am. J. Respir. Crit. Care Med. 2006;173:1056-1065.
FULL TEXT